Lin Tu

Lin Tu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2014 in BMC Surgery
Verified
Journal Article
Open access
PDF file
MWMing Wang
Ming Wang
JXJia Xu
Jia Xu
YZYun Zhang
Yun Zhang
LTLin Tu
Lin Tu
WQWei-Qing Qiu
Wei-Qing Qiu
HCHui Cao
Hui Cao
Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is difficult to predict its malignant potential. The aim of this study is to explore the characteristics and prognostic factors of GIST. Clinical and pathological data of 497 GIST patients in our center between 1997 and 2012 were reviewed. Patients were categorized into very low-, low-, intermediate- and high-risk groups according to modified National Institutes of Health (NIH) consensus classification system. Among the 401 patients untreated with imatinib mesylate (IM), 5-year overall survival (OS) in very low-, low-, intermediate- and high-risk groups was 100%, 100%, 89.6% and 65.9%; and 5-year relapse-free survival (RFS) was 100%, 98.1%, 90.9% and 44.5%, respectively. Univariate analysis revealed that sex, tumor size, mitotic rate, risk grade, CD34 expression, and adjacent involvement were predictors of OS or RFS. COX hazard proportional model (Forward LR) showed that large tumor size, high mitotic rate, and high risk grade were independent risk factors to OS, whereas high mitotic rate, high risk grade and adjacent organ involvement were independent risk factors to RFS. The intermediate-high risk patients who received IM adjuvant therapy (n = 87) had better 5-year OS and RFS than those who did not (n = 188) (94.9% vs. 72.1; 82.3% vs. 56.3%, respectively). Similarly, advanced GIST patients underwent IM therapy (n = 45) had better 3-year OS and 1-year progression-free survival (PFS) than those who didn’t (n = 42) (75.6% vs. 6.8%; 87.6% vs. 12.4%, respectively). Very low- and low-risk GISTs can be treated with surgery alone. Large tumor size, high mitotic rate, high risk grade, and adjacent organ involvement contribute to the poor outcome. IM therapy significantly improves the survival of intermediate-high risk or advanced GIST patients.

14 May 2020 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
YSYan-Ying Shen
Yan-Ying Shen
XMXin-Li Ma
Xin-Li Ma
LYLin-Xi Yang
Lin-Xi Yang
WZWen-Yi Zhao
Wen-Yi Zhao
LTLin Tu
Lin Tu
HCHui Cao
Hui Cao
Most sporadic gastrointestinal stromal tumors (GISTs) occur as solitary tumors, while multiple sporadic GISTs are extremely rare and often misdiagnosed as metastatic GISTs, leading to inappropriate treatment. This study aimed to investigate the clinicopathological characteristics, diagnostic clues, and prognoses of multiple sporadic GISTs. Twenty-seven patients with multiple sporadic GISTs and 11 patients with metastatic GISTs mimicking sporadic GISTs were analyzed. The clinicopathological characteristics, genetic mutation types, and prognoses were summarized. In addition, 1066 cases of primary GISTs with a single lesion diagnosed at the same hospital were included as controls. Compared with 1066 cases of primary GIST with a single lesion, multiple sporadic GISTs occurred at an older age, were more common in women than in men, and were located mainly in the stomach. They were generally small in size, had a low mitotic index and were more often rated as very low risk/low risk. Mutation analysis of all available lesions revealed different KIT/PDGFRA mutation patterns among tumors from the same patients. No patient relapsed during the follow-up period. Among 11 patients with metastatic GISTs that mimicked multiple sporadic GISTs, multiple lesions from the same patient always had concordant pathological and mutational characteristics; namely, they carried an identical KIT/PDGFRA mutation, and the mitotic index was usually high. The prognoses of patients with multiple sporadic GISTs were not worse than those of patients with a single lesion of the same risk under the same treatment. When it was difficult to distinguish multiple sporadic GISTs from metastatic GISTs, multiple lesions in the same patient carried different KIT/PDGFRA mutation patterns, which supported tumor multiplicity, while the concordant hypermitotic phase in multiple lesions of GISTs suggested that the tumor was metastatic.

7 June 2014 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
WZWen-Yi Zhao
Wen-Yi Zhao
JXJia Xu
Jia Xu
MWMing Wang
Ming Wang
ZZZi-Zhen Zhang
Zi-Zhen Zhang
LTLin Tu
Lin Tu
ZZZhi-Gang Zhang
Zhi-Gang Zhang
Although the clinical benefit of imatinib adjuvant therapy for high-risk patients with gastrointestinal stromal tumor (GIST) has been proven, the recurrence rate still remains high. This study aimed to sub-divide high-risk GIST patients with some “very high-risk” factors for more precise prognostic indicator, and possible association with efficiency of imatinib adjuvant therapy.

17 February 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
CZChun Zhuang
Chun Zhuang
BNBo Ni
Bo Ni
ZZZi-Zhen Zhang
Zi-Zhen Zhang
WZWen-Yi Zhao
Wen-Yi Zhao
LTLin Tu
Lin Tu
MWMing Wang
Ming Wang
There are multiple tumor-infiltrating lymphocytes (TILs) and relevant immune checkpoints existing in gastrointestinal stromal tumor (GIST), which provides opportunities and rationales for developing effective immunotherapies. Recent studies have suggested that checkpoint TIM-3/Gal-9 plays a pivotal role on immune response in multiple tumors, similar to the PD-1/PD-L1, emerging as a potential therapeutic target. However, their functions in GIST are unrevealed. Hence, the expression of immune checkpoints TIM-3 and Gal-9, as well as the infiltration of CD8+ T cells and NK cells, is described in 299 cases of GIST specimens. The results showed that TIM-3 and Gal-9 are mainly expressed in TILs, rarely in tumor cells. Expression levels of TIM-3 and Gal-9 significantly differ in varying risks of GIST and exert opposite distribution trends. Indicated by prognosis analysis, high TIM-3 expression of TILs was associated with improved outcome, while low expression levels of TIM-3 in combination with low amounts of CD8+ and CD56+ TILs predict extremely poor survival. The integrated analysis of TIM-3+, CD8+, and CD56+ TILs as one biomarker is a reliable independent predictor of prognosis. In conclusion, low densities of TIM-3+ TILs are associated with poor survival, and integrated immune biomarkers lead to superior predictors of GIST prognosis.

1 January 2023
Verified
Journal Article
Closed access
CHChen Huang
Chen Huang
MWMing Wang
Ming Wang
WZWen-Yi Zhao
Wen-Yi Zhao
YSYan-Ying Shen
Yan-Ying Shen
CZChun Zhuang
Chun Zhuang
HCHui Cao
Hui Cao

10 November 2026 in Gut
Verified
Journal Article
Closed access
CZChunling Zeng
Chunling Zeng
YXYangjie Xiong
Yangjie Xiong
HLHaoqi Lan
Haoqi Lan
YPYuzhi Pang
Yuzhi Pang
YLYuxiang Luo
Yuxiang Luo
YWYuexiang Wang
Yuexiang Wang